Active repression of antiapoptotic gene expression by RelA(p65) NF-κB

Molecular Cell

Volumn 13, Issue 6, 2004, Pages 853-865

  Campbell, Kirsteen J ^a   Rocha, Sonia ^a   Perkins, Neil D ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DAUNORUBICIN; DOXORUBICIN; HISTONE DEACETYLASE; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR;

ANIMAL CELL; APOPTOSIS; ARTICLE; CYTOTOXICITY; EMBRYO; FIBROBLAST; GENE EXPRESSION; GENE REPRESSION; MOUSE; NONHUMAN; STIMULUS RESPONSE; ULTRAVIOLET RADIATION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BONE NEOPLASMS; CELL LINE, TUMOR; CELLS, CULTURED; DAUNORUBICIN; DNA, NEOPLASM; DOXORUBICIN; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HISTONE DEACETYLASES; HUMANS; KINETICS; MICE; NF-KAPPA B; PROMOTER REGIONS (GENETICS); RNA, MESSENGER; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTOR RELA; TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEINS; ULTRAVIOLET RAYS;

ANIMALIA;

EID: 1842526076     PISSN: 10972765     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1097-2765(04)00131-5     Document Type: Article

References (43)

1. Anderson L.A., Perkins N.D. Regulation of RelA (p65) function by the large subunit of replication factor C. Mol. Cell. Biol. 23:2003;721-732.
2. Arlt A., Vorndamm J., Breitenbroich M., Folsch U.R., Kalthoff H., Schmidt W.E., Schafer H. Inhibition of NF-κB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene. 20:2001;859-868.
3. Ashburner B.P., Westerheide S.D., Baldwin A.S. The p65 (RelA) subunit of NF-κB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol. Cell. Biol. 21:2001;7065-7077.
4. Baldwin A.S. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J. Clin. Invest. 107:2001;241-246.
5. Barkett M., Gilmore T.D. Control of apoptosis by Rel/NF-κB transcription factors. Oncogene. 18:1999;6910-6924.
6. Beg A.A., Baltimore D. An essential role for NF-κB in preventing TNF-α-induced cell death. Science. 274:1996;782-784.
7. Bender K., Gottlicher M., Whiteside S., Rahmsdorf H.J., Herrlich P. Sequential DNA damage-independent and -dependent activation of NF-κB by UV. EMBO J. 17:1998;5170-5181.
8. Boland M.P., Foster S.J., O'Neill L.A.J. Daunorubicin activates NF κB and induces κB-dependent gene expression in HL-60 promyelocytic and Jurkat T lymphoma cells. J. Biol. Chem. 272:1997;12952-12960.
9. Bottero V., Busuttil V., Loubat A., Magne N., Fischel J.L., Milano G., Peyron J.F. Activation of nuclear factor κB through the IKK complex by the topoisomerase poisons SN38 and doxorubicin. a brake to apoptosis in HeLa human carcinoma cells Cancer Res. 61:2001;7785-7791.
10. Campbell K.J., Chapman N.R., Perkins N.D. UV stimulation induces nuclear factor κB (NF-κB) DNA-binding activity but not transcriptional activation. Biochem. Soc. Trans. 29:2001;688-691.
11. Chen C.L., Edelstein L.C., Gelinas C. The Rel/NF-κB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol. Cell. Biol. 20:2000;2687-2695.
12. Chen L.F., Fischle W., Verdin E., Greene W.C. Duration of nuclear NF-κB action regulated by reversible acetylation. Science. 293:2001;1653-1657.
13. Chen L.F., Mu Y.J., Greene W.C. Acetylation of ReIA at discrete sites regulates distinct nuclear functions of NF-κB. EMBO J. 21:2002;6539-6548.
14. Dajee M., Lazarov M., Zhang J.Y., Cai T., Green C.L., Russell A.J., Marinkovich M.P., Tao S.Y., Lin Q., Kubo Y.et al. NF-κB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature. 421:2003;639-643.
15. Gapuzan M.E.R., Yufit P.V., Gilmore T.D. Immortalized embryonic mouse fibroblasts lacking the RelA subunit of transcription factor NF-κB have a malignantly transformed phenotype. Oncogene. 21:2002;2484-2492.
16. Gewirtz D.A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics Adriamycin and daunorubicin. Biochem. Pharmacol. 57:1999;727-741.
17. Ghosh S., May M.J., Kopp E.B. NF-κB and rel proteins. evolutionarily conserved mediators of immune responses Annu. Rev. Immunol. 16:1998;225-260.
18. Huang T.T., Feinberg S.L., Suryanarayanan S., Miyamoto S. The zinc finger domain of NEMO is selectively required for NF-κB activation by UV radiation and topoisomerase inhibitors. Mol. Cell. Biol. 22:2002;5813-5825.
19. Israel A. Signal transduction - a regulator branches out. Nature. 423:2003;596-597.
20. Ito K., Barnes P.J., Adcock I.M. Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1 beta-induced histone H4 acetylation on lysines 8 and 12. Mol. Cell. Biol. 20:2000;6891-6903.
21. Kaltschmidt B., Kaltschmidt C., Hofmann T.G., Hehner S.P., Droge W., Schmitz M.L. The pro- or anti-apoptotic function of NF-κB is determined by the nature of the apoptotic stimulus. Eur. J. Biochem. 267:2000;3828-3835.
22. Karin M., Ben-Neriah Y. Phosphorylation meets ubiquitination. the control of NF-κB activity Annu. Rev. Immunol. 18:2000;621-623.
23. Kasibhatla S., Brunner T., Genestier L., Echeverri F., Mahboubi A., Green D.R. DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-κB and AP-1. Mol. Cell. 1:1998;543-551.
24. Kato T., Delhase M., Hoffmann A., Karin M. CK2 is a C-terminal IκB kinase responsible for NF-κB activation during the UV response. Mol. Cell. 12:2003;829-839.
25. Kiernan R., Bres V., Ng R.W.M., Coudart M.P., El Messaoudi S., Sardet C., Jin D.Y., Emiliani S., Benkirane M. Post-activation turn-off of NF-κB-dependent transcription is regulated by acetylation of p65. J. Biol. Chem. 278:2003;2758-2766.
26. Koong A.C., Chen E.Y., Giaccia A.J. Hypoxia causes the activation of nuclear factor kappa-B through the phosphorylation of IκB-α on tyrosine residues. Cancer Res. 54:1994;1425-1430.
27. Lavon I., Pikarsky E., Gutkovich E., Goldberg I., Bar J., Oren M., Ben-Neriah Y. Nuclear factor-κB protects the liver against genotoxic stress and functions independently of p53. Cancer Res. 63:2003;25-30.
28. Lin A., Karin M. NF-κB in cancer. a marked target Semin. Cancer Biol. 13:2003;107-114.
29. Minocha A., Long B.H. Inhibition of the DNA catenation activity of type-II topoisomerase by Vp16-213 and Vm26. Biochem. Biophys. Res. Commun. 122:1984;165-170.
30. Pahl H.L. Activators and target genes of Rel/NF-κB transcription factors. Oncogene. 18:1999;6853-6866.
31. Rocha S., Campbell K.J., Perkins N.D. p53- and Mdm2-independent repression of NF-κB transactivation by the ARF tumour suppressor. Mol. Cell. 12:2003;15-25. a.
32. Rocha S., Martin A.M., Meek D.W., Perkins N.D. p53 represses Cyclin D1 transcription through down regulation of Bcl-3 and inducing increased association of the p52 NF-κB subunit with Histone Deacetylase 1. Mol. Cell. Biol. 23:2003;4713-4727. b.
33. Ryan K.M., Ernst M.K., Rice N.R., Vousden K.H. Role of NF-κB in p53-mediated programmed cell death. Nature. 404:2000;892-897.
34. Saccani S., Pantano S., Natoli G. Two waves of nuclear factor κB recruitment to target promoters. J. Exp. Med. 193:2001;1351-1359.
35. Saccani S., Pantano S., Natoli G. Modulation of NF-κB activity by exchange of dimers. Mol. Cell. 11:2003;1563-1574.
36. Sizemore N., Lerner N., Dombrowski N., Sakurai H., Stark G.R. Distinct roles of the IκB kinase α and beta subunits in liberating nuclear factor κB (NFκB) from IκB and in phosphorylating the p65 subunit of NF-κB. J. Biol. Chem. 277:2002;3863-3869.
37. Spalding A.C., Jotte R.M., Scheinman R.I., Geraci M.W., Clarke P., Tyler K.L., Johnson G.L. TRAIL and inhibitors of apoptosis are opposing determinants for NF-κB-dependent, genotoxin-induced apoptosis of cancer cells. Oncogene. 21:2002;260-271.
38. Tergaonkar V., Bottero V., Ikawa M., Li Q.T., Verma I.M. IκB kinase-independent IκBα degradation pathway. functional NF-κB activity and implications for cancer therapy Mol. Cell. Biol. 23:2003;8070-8083.
39. Vermeulen L., De Wilde G., Notebaert S., Vanden Berghe W., Haegeman G. Regulation of the transcriptional activity of the nuclear factor-κB p65 subunit. Biochem. Pharmacol. 64:2002;963-970.
40. Wang C., Mayo M.W., Baldwin A.S. TNF- and cancer therapy-induced apoptosis. potentiation by inhibition of NF-κB Science. 274:1996;784-787.
41. Wang S.W., Kotamraju S., Konorev E., Kalivendi S., Joseph J., Kalyanaraman B. Activation of nuclear factor-κB during doxorubicin-induced apoptosis in endothelial cells and myocytes is pro-apoptotic. the role of hydrogen peroxide Biochem. J. 367:2002;729-740.
42. Webster G.A., Perkins N.D. Transcriptional cross talk between NF-κB and p53. Mol. Cell. Biol. 19:1999;3485-3495.
43. Zhong H.H., May M.J., Jimi E., Ghosh S. The phosphorylation status of nuclear NF-κB determines its association with CBP/p300 or HDAC-1. Mol. Cell. 9:2002;625-636.